Sunitinib, 98%, a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively

Cat. No JK381939_50_MG

Vendor: J&K Chemical

Product Information

Product Name

Brand Name

J&K

Product Number

381939

CAS

557795-19-4

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

5329102

IUPAC Name

N-2-(diethylamino)ethyl-5-(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl-2,4-dimethyl-1H-pyrrole-3-carboxamide

InChI Key

WINHZLLDWRZWRT-ATVHPVEESA-N

SMILES

CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C

Safety Information

Storage Condition

Freezer -20℃

References

[Is the adjuvant administration of imatinib more meaningful over 3 or 6 years in patients with high-risk for recurrent GIST?]

Publication Name: Chirurgie (Heidelberg, Germany)

Publication Date: 2025-09

DOI: 10.1007/s00104-025-02350-8

PD-1/PD-L1 Inhibitors Increase Pathological Complete Response in Locally Advanced Gastric Cancer: A Meta-analysis and Trial Sequential Analysis

Publication Name: Journal of Gastrointestinal Cancer

Publication Date: 2025-08-26

DOI: 10.1007/s12029-024-01141-4|10.1007/s12029-025-01204-0|10.1007/s12029-025-01305-w

Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial

Publication Name: Nature Medicine

Publication Date: 2025-08-01

DOI: 10.1038/s41591-025-03867-5

CYP1B1 promotes angiogenesis and sunitinib resistance in clear cell renal cell carcinoma via USP5-mediated HIF2α deubiquitination

Publication Name: Neoplasia (New York, N.Y.)

Publication Date: 2025-08

DOI: 10.1016/j.neo.2025.101186

Biomarkers for renal cell carcinoma — a pragmatic approach

Publication Name: Nature reviews. Urology

Publication Date: 2025-07-30

DOI: 10.1038/s41585-025-01073-z

Sunitinib, 98%, a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively

Product Information

General Information

Safety Information

References

[Is the adjuvant administration of imatinib more meaningful over 3 or 6 years in patients with high-risk for recurrent GIST?]

PD-1/PD-L1 Inhibitors Increase Pathological Complete Response in Locally Advanced Gastric Cancer: A Meta-analysis and Trial Sequential Analysis

Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial

CYP1B1 promotes angiogenesis and sunitinib resistance in clear cell renal cell carcinoma via USP5-mediated HIF2α deubiquitination

Biomarkers for renal cell carcinoma — a pragmatic approach